A Research Guide for
Beta-Thalassemia

Complete blood count (CBC). Beta-thalassemia produces small (microcytic) red cells with a low mean corpuscular volume (MCV) and low mean corpuscular hemoglobin (MCH). The same pattern occurs in iron deficiency, so the two have to be sorted out before any diagnosis is made.

Iron studies. Ferritin, transferrin saturation, and serum iron. These tell whether the small red cells are from iron deficiency, iron overload, or neither.

Hemoglobin analysis (high-performance liquid chromatography or capillary electrophoresis). This separates and measures the different hemoglobin types. In beta-thalassemia, HbA2 is usually elevated and HbF (fetal hemoglobin) may be higher than normal.

Genetic testing of the HBB gene. This identifies the specific mutation(s). More than 200 different beta-globin mutations have been described worldwide, and which ones you carry helps predict severity and informs reproductive counseling.

Baseline organ assessment if you are being followed long-term: liver function tests, kidney function, endocrine screen (thyroid, glucose, parathyroid), vitamin D, and eventually cardiac and liver iron MRI.

In Utah and most of the United States, newborn screening primarily targets sickle cell disease but often detects severe thalassemia syndromes incidentally. If a baby shows an unusual hemoglobin pattern at birth, your pediatrician will refer to a hematologist for confirmation. Early diagnosis is genuinely valuable: starting transfusion and chelation before complications appear is much better than catching up later.

You carry two copies of the beta-globin gene. Each can be one of three broad types: normal (often written as β), a mutation that allows reduced but not zero beta-globin production (β⁺), or a mutation that allows essentially no beta-globin production (β⁰). Your two copies combine to determine severity.

• β⁰/β⁰ — the most severe form, with no functional beta-globin produced. Almost always transfusion-dependent.
• β⁺/β⁰ and β⁺/β⁺ — intermediate, ranging from transfusion-dependent to transfusion-independent depending on which specific mutations are involved.
• HbE/β-thalassemia — very common in Southeast Asia. One copy carries the HbE variant and the other a beta-thalassemia mutation. The clinical picture is unpredictable; some patients are transfusion-dependent, others are not.

Other factors also affect severity, including a separate gene that controls fetal hemoglobin production. Two patients with identical beta-globin genotypes can have surprisingly different clinical courses.

• What is my (or my child's) specific beta-globin genotype, and what does it predict about disease severity?
• Do I have a β⁰/β⁰ genotype, and if so, what does that mean for treatment options including gene therapy?
• Has my fetal hemoglobin (HbF) level been measured? Are there modifier genes that might affect my course?
• What is my baseline iron status, and when should I have my first MRI of the heart and liver?
• Are my siblings, parents, or children being offered carrier testing?
• If I am planning a pregnancy, has my partner been tested? Is genetic counseling available?
• What records should I keep so a future hematologist or transplant team can review my history quickly?

Most adult patients with TDT receive 2–3 units of red cells every 3–4 weeks. Children's volumes are weight-adjusted. Sessions typically last 3–5 hours.

Before each transfusion: bloodwork is drawn to check pre-transfusion hemoglobin, antibody screen, and sometimes ferritin or liver function. The blood bank crossmatches a unit specifically for you.

During: nursing watches for transfusion reactions (fever, chills, hives, breathing changes, back pain). Modern blood is highly screened, but mild allergic reactions still happen occasionally.

After: most people feel notably better for the first 1–2 weeks, then progressively more tired as the new cells age and hemoglobin drops back toward the next transfusion. Tracking how you feel through this cycle is useful information for adjusting timing or trying disease-modifying therapy.

After repeated transfusions, the immune system can start making antibodies against minor blood group antigens it has not seen before. Once antibodies form, finding compatible blood gets harder, and reactions become more likely. Most thalassemia programs now use extended antigen matching from the start: matching for C, c, E, e, and Kell antigens, not just ABO and Rh.

Tell every transfusion provider about any antibodies you have ever developed. Carry a card if possible. This is one of the highest-value pieces of medical history you own.

The human body has no normal way to get rid of large amounts of iron. Each unit of transfused red cells delivers about 200–250 milligrams of iron. Over a year of transfusion, that adds up to several grams of iron with nowhere to go. The body stores the excess in the liver, the heart, the pancreas, the thyroid, the pituitary, and the gonads. Untreated, this causes liver fibrosis, heart failure, diabetes, hypothyroidism, infertility, and growth failure.

Cardiac iron overload was the leading cause of death in TDT for decades, and most of those deaths happened before chelation was working as well as it does today. The introduction of cardiac T2* MRI — which measures heart iron specifically — allowed targeted treatment and was directly associated with declining mortality in long-term follow-up of Italian patients.

Deferoxamine (Desferal) is the oldest chelator and remains highly effective. It is given as a slow subcutaneous infusion via a small pump, typically over 8–12 hours, 5–7 nights a week. It excels at removing liver iron and has the longest track record. Its main downside is the burden of nightly infusions, which makes adherence the central challenge.

Deferasirox (Exjade as a dispersible tablet; Jadenu as a film-coated tablet or oral granules) is taken by mouth once a day. It is the most widely used first-line chelator in the US. It is generally well tolerated but requires monitoring of kidney function, liver enzymes, and rarely vision and hearing. Jadenu is generally easier to swallow than the older Exjade tablets.

Deferiprone (Ferriprox) is taken by mouth three times a day. It is particularly good at removing iron from the heart and is sometimes added to deferasirox or deferoxamine when cardiac iron is high. Its main safety concern is a small risk of dangerously low neutrophil counts; weekly blood counts are recommended.

Many adults use combination chelation — for example deferasirox plus deferiprone — to target both the liver and the heart aggressively. There is no universal best regimen; the best regimen is the one that brings your numbers down and that you can actually take consistently.

Serum ferritin every 1–3 months. A rough but useful indicator of body iron over time. Trends matter more than single values.

Liver iron concentration by MRI (R2 or R2*) yearly. The most reliable measure of liver iron load.

Cardiac T2* MRI yearly from around age 8–10 onward. A T2* below 20 milliseconds suggests cardiac iron loading; below 10 milliseconds is high-risk and usually triggers intensified chelation.

Endocrine screening yearly. Thyroid function, fasting glucose, calcium, vitamin D, growth velocity in children, puberty staging, gonadal function in adults.

Bone density every 1–2 years in adults. Osteoporosis is common in thalassemia.

• What is my current pre-transfusion hemoglobin target, and how is it being met?
• What is my extended red cell antigen profile, and is my blood bank using extended matching?
• What were my most recent liver iron concentration (LIC) and cardiac T2* values, and how have they trended?
• Is my chelation regimen meeting its goals, and are there safety labs I should be tracking on my own?
• If I am missing doses, what is a realistic schedule we could agree on instead?
• Am I a candidate for luspatercept or mitapivat to reduce transfusion burden?
• When should I have my next MRI, and where is it done locally?

Luspatercept is a once-every-three-weeks injection given under the skin. It is engineered to act on a specific signaling pathway in the bone marrow that is overactive in beta-thalassemia, allowing late-stage red blood cell development to proceed more normally.

For transfusion-dependent thalassemia, the pivotal BELIEVE trial and its long-term extension showed reduced red cell transfusion requirements in a significantly larger proportion of patients receiving luspatercept compared with placebo, with a manageable safety profile.

For non-transfusion-dependent thalassemia, the BEYOND trial met its primary endpoint (about 77% of treated patients achieved a sustained hemoglobin rise of at least 1 g/dL over a continuous 12-week window, versus none on placebo); across any 12-week interval during longer follow-up roughly 95% achieved such a response, with improvements in fatigue and weakness.

Common side effects include bone pain (often early in treatment and improving over time), fatigue, headache, and joint pain. Less commonly, blood clots can occur, especially in patients who have had their spleen removed. Iron parameters generally improve over time on luspatercept because transfusion need decreases.

Luspatercept is FDA-approved for TDT in adults. For NTDT it is approved in Europe but is not FDA-approved in the United States (the US NTDT application was withdrawn in 2022), so US use in NTDT would be off-label.

Mitapivat is a twice-daily oral pill that activates an enzyme called pyruvate kinase, helping red cells produce energy more efficiently and survive longer. In late 2025 the FDA approved mitapivat (sold as Aqvesme in the US for thalassemia) for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, and in mid-2026 the European Commission approved it under the Pyrukynd name.

In the ENERGIZE trial (NTDT), roughly 42% of patients on mitapivat achieved a hemoglobin response of at least 1 g/dL compared with under 2% on placebo. In ENERGIZE-T (TDT), a significantly higher proportion of patients on mitapivat achieved at least a 50% reduction in transfusion volume compared with placebo.

Safety note: a small number of patients in trials developed signs of liver injury, which led the FDA to require a Risk Evaluation and Mitigation Strategy (REMS) program. Liver function tests are monitored regularly. Patients also cannot stop mitapivat abruptly; tapering is required to avoid sudden hemolysis.

For some patients, an oral pill with no injections will fit life better than a once-every-three-weeks shot. For others, the injection schedule of luspatercept is preferable. There is no head-to-head trial; the choice is individualized.

• Folic acid: Daily folic acid supports the increased red cell production that ineffective erythropoiesis demands.
• Vitamin D and calcium: Bone disease is common in thalassemia. Vitamin D deficiency is almost universal and should be corrected.
• Bisphosphonates or denosumab: For adults with established osteoporosis.
• Hormone replacement: Many adults need thyroid replacement, testosterone or estrogen, and occasionally growth hormone in children. These reflect iron-related endocrine damage and are very treatable when caught.
• Hydroxyurea: Mainly used in NTDT and selected TDT cases to nudge fetal hemoglobin production upward. Response varies.

• Am I a candidate for luspatercept or mitapivat, and what would success look like for me?
• What blood tests will be monitored on each medication, and how often?
• If I am on luspatercept, am I at higher risk of blood clots given my splenectomy status or other risk factors?
• If I am on mitapivat, what should I do if I miss a dose or run out, and how is liver monitoring handled?
• How will we know whether the medication is working — what is the timeline?
• What is the plan if it does not work or stops working?
• How is insurance coverage handled for these specialty medications, and what specialty pharmacy will I use?

HSCT replaces your bone marrow with stem cells from a donor whose own blood cells make hemoglobin normally. It has been used to cure thalassemia for over 40 years, most famously at the program in Pesaro, Italy, where the modern protocols were developed.

Best outcomes: Children under 14 transplanted from an HLA-matched sibling donor, before iron-related organ damage has accumulated, have thalassemia-free survival above 90%.

The donor question: Only about a quarter to a third of patients have a fully matched sibling donor. For everyone else, options include matched unrelated donors and, more recently, haploidentical (half-matched) donors — usually a parent or sibling. With newer protocols using post-transplant cyclophosphamide for graft-versus-host disease prevention, recent pediatric studies have shown overall survival around 92% and thalassemia-free survival above 84% even with haploidentical donors.

Main risks: Graft-versus-host disease (the donor immune cells attacking the recipient), infections during the immune-recovery period, organ toxicity from conditioning chemotherapy, infertility, and a small risk of secondary cancers years later.

HSCT for thalassemia is performed at a relatively small number of centers worldwide with deep experience in this specific condition. Volume matters — outcomes are best at high-volume programs.

Casgevy (exagamglogene autotemcel) is the world's first approved CRISPR gene-editing therapy. The patient's own stem cells are collected, edited in the lab to disable a gene called BCL11A in the cells that become red blood cells, and re-infused. With BCL11A switched off, the body resumes making fetal hemoglobin — the form normally turned off shortly after birth — in large enough amounts to compensate for the broken adult hemoglobin. Casgevy was FDA-approved for TDT in January 2024.

In long-term follow-up across the CLIMB phase 3 program presented through 2025, the great majority of TDT patients achieved freedom from transfusion for at least 12 consecutive months with weighted average hemoglobin of at least 9 g/dL, and the longest-followed patients are now beyond six years post-treatment with sustained benefit.

Zynteglo (betibeglogene autotemcel, "beti-cel") uses a different strategy: a lentiviral vector delivers a functional copy of the beta-globin gene into the patient's stem cells. It was FDA-approved for TDT in 2022. Real-world data through 2025–2026 confirm durable hemoglobin A production and transfusion independence consistent with the clinical trial results, with the longest-followed patients now beyond 10 years. Zynteglo was withdrawn from the European market in 2022 due to commercial — not safety — reasons, although it remains available in the US.

Eligibility (TDT only): Casgevy is FDA-approved for transfusion-dependent patients aged 12 and older. The US Zynteglo label is broader — adult and pediatric patients with TDT, with no fixed lower age cutoff and no requirement to lack a matched sibling donor (the “no matched sibling donor” restriction applied to Zynteglo’s former EU authorization, not the US label). Both require the ability to tolerate myeloablative conditioning.

From referral to home, the timeline is typically 6–12 months.

1. Evaluation and eligibility (weeks to months). Detailed cardiac, liver, and infection workup; psychosocial assessment; fertility preservation counseling.
2. Cell collection (apheresis). Stem cells are mobilized into the bloodstream and collected over one to several days. This typically requires hospitalization and several weeks of preparation.
3. Cell manufacturing. Your cells are shipped to a specialized facility where they are edited (Casgevy) or have the gene added (Zynteglo), then expanded and quality-tested. This takes several months.
4. Conditioning chemotherapy. Inpatient busulfan, given over several days to clear out the existing bone marrow. This is the hardest physical part — nausea, hair loss, mucositis, and a deep period of low blood counts.
5. Infusion of the modified cells. A single infusion, the actual "gene therapy" moment, which usually takes less than an hour.
6. Engraftment and recovery (weeks). The new cells take hold and start producing blood. Hospital stay is typically 4–6 weeks.
7. Long-term follow-up. Frequent visits in the first year, gradually tapering. Monitoring continues for at least 15 years because of the theoretical risk of insertional mutagenesis and secondary cancers.

Casgevy is priced at approximately $2.2 million per patient in the United States; Zynteglo at approximately $2.8 million. These are list prices; insurance arrangements, value-based agreements, and outcome-based contracts are how patients actually access these therapies in practice. Specialty pharmacy navigators and patient advocacy organizations are essential.

Globally, gene therapy access is concentrated in the US, parts of Europe, and a small number of Gulf states. The patients who most need cure — in India, Pakistan, Thailand, and parts of the Middle East — largely cannot access these therapies today. This is one of the most pressing equity questions in medicine.

If you have a fully matched sibling donor and are young, matched sibling HSCT is usually considered first because of its very long track record, lower cost, and excellent outcomes in low-risk patients. If you do not have a matched sibling donor, the comparison gets more interesting and the choice depends on your age, genotype, organ status, fertility plans, and what centers are accessible to you.

The current TIF guidelines (5th edition, 2025) suggest HSCT from an HLA-identical sibling donor is highly effective for children up to 14 with TDT, especially in regions without gene therapy access. They also explicitly recognize gene therapy as a curative option where available.

• Am I a candidate for curative therapy — and if so, which one(s)?
• Do I have a matched sibling, matched unrelated, or only haploidentical donor option?
• What are the survival, cure, and complication rates at the specific center being recommended to me?
• What fertility preservation options should I pursue before conditioning, and when must I act?
• What is the realistic timeline from decision to discharge?
• What does long-term monitoring look like after the transplant or gene therapy is "done"?
• If insurance is the limiting factor, what financial counselors, value-based agreements, or foundation support exist?
• How will my chelation and existing iron load be managed before and after the procedure?

If you are well-transfused, your energy will rise and fall through the transfusion cycle. Most patients feel best in the first 1–2 weeks after transfusion and notice fatigue creeping back as the next is due. Tracking this is useful: large mood or energy swings between cycles may mean the pre-transfusion target is set too low.

Exercise is encouraged and safe for most. Aerobic exercise supports cardiac health, which is especially important given the long-term cardiac risks. Resistance training supports bone health. Talk to your cardiologist before starting a vigorous program if you have any history of cardiac iron loading or cardiomyopathy.

Avoid iron supplements unless specifically prescribed. Multivitamins "with iron" are not appropriate for most TDT patients. Always check labels.

Tea with meals (especially black or green tea) reduces iron absorption from food and is a low-cost adjunctive measure in NTDT.

Vitamin C can increase the toxicity of free iron. Most teams recommend keeping supplemental vitamin C modest and avoiding mega-doses, especially around chelation timing.

Calcium and vitamin D are nearly universal recommendations because of bone disease risk.

Alcohol stresses an already iron-burdened liver and is best minimized.

Many adults with well-managed TDT can become parents, but the path often requires fertility specialists. Iron-related damage to the pituitary and gonads commonly affects natural fertility; assisted reproduction is frequently used.

Before conditioning chemotherapy for transplant or gene therapy, fertility preservation (sperm banking, egg or embryo cryopreservation, or in some cases ovarian tissue preservation) should be discussed. The window to act is before, not after.

Pregnancy in thalassemia requires planning: optimize iron status (especially cardiac iron) before conception, pause certain chelators (deferasirox and deferiprone are not used in pregnancy; deferoxamine may be continued in the second and third trimesters), increase transfusion frequency to maintain hemoglobin, and follow with maternal-fetal medicine plus hematology.

Carrier testing of partners is strongly recommended.

The relentlessness of transfusions, chelation, side effects, and uncertainty takes a real psychological toll. Depression and anxiety are common and treatable. Asking for a referral to a psychologist or social worker familiar with chronic illness is reasonable and useful at any age.

For young adults, the transition from pediatric care — often felt as supportive and family-centered — to adult hematology can be jarring. Plan that transition deliberately and meet the adult team at least once while still under pediatric care.

• New shortness of breath, swelling in the legs, or sudden weight gain (possible cardiac iron complications)
• Chest pain or palpitations
• Fever, especially if you have had your spleen removed (post-splenectomy infections can be rapid and severe)
• Severe abdominal pain or yellowing of the skin/eyes
• Sudden severe headache, vision changes, or stroke-like symptoms
• Severe or unusual bleeding or bruising
• Symptoms of a transfusion reaction in the hours after transfusion: fever, chills, back pain, dark urine, breathing problems
• Signs of low blood counts on deferiprone: high fever, sore throat, mouth ulcers

If you are caring for a child or adult with beta-thalassemia, the practical work of this disease is largely carried by you alongside the patient. A few things experienced caregivers consistently say they wish they had known earlier.

Build the binder. Keep one place — physical or digital — with the genotype report, the current chelation prescription and dose, the most recent MRI values, the list of antibodies, the transfusion schedule, the vaccination record, and a one-page summary you can hand to a new clinician or emergency room. This binder will save hours during your child's life.

Build the routine around chelation. Adherence is the single biggest determinant of long-term outcome that is actually under your control. For young children on oral chelation, link the dose to an unmissable daily event (breakfast, after teeth-brushing). For adolescents starting to manage their own care, hand off gradually and openly. For adults on subcutaneous deferoxamine, treat the infusion pump like a piece of equipment that has to be maintained, not just used.

Plan transfusions around life, not the other way around. Most programs can accommodate after-school or after-work scheduling. Missed school or work for transfusions adds up; advocacy for accommodations under disability law (in the US, Section 504 plans and IEPs in schools, FMLA for adults) is often necessary and effective.

Watch for signs of iron-related endocrine changes. A child who stops growing, a teenager whose puberty does not start on time, an adult whose energy drops unexpectedly — these can all be hormonal effects of iron that are very treatable when caught early. Many caregivers are the first to notice.

Navigate insurance proactively. Specialty pharmacy for chelation and disease-modifying drugs is its own bureaucratic ecosystem. Identify a specialty pharmacy coordinator at your insurance plan and at the hematology center. Renew prior authorizations weeks before they expire, not days.

Take care of yourself. Caregiver burnout is real and degrades the quality of care you can provide. Use respite care, lean on patient organizations, and consider a therapist who works with chronic-illness families. The marathon analogy is overused but accurate.

Talk about cure honestly. If gene therapy or transplant is on the table, the decision belongs to the patient when they are old enough to participate. Bring them in early. The conversation about fertility, time off school or work, and acceptance of risk is one no one else can have for them.

• Thalassaemia International Federation (TIF) — the global patient organization. Publishes free guidelines used by clinicians worldwide and operates patient education programs.
• Cooley's Anemia Foundation (United States) — patient and family support, education, advocacy, and research funding.
• Thalassemia Support Foundation — patient support and education.
• National Organization for Rare Disorders (NORD) — disease information and financial assistance resources for rare diseases including thalassemia.

• University of Utah Health Hematology — adult hematology including hemoglobinopathy expertise; access to clinical trials.
• Intermountain Health — adult and pediatric hematology, transfusion medicine, and laboratory services across the Wasatch Front and beyond.
• Primary Children's Hospital (Intermountain Health) — pediatric hematology including thalassemia care, with referral pathways to adult care.
• ARUP Laboratories (Salt Lake City) — one of the leading reference labs in the US for hemoglobin testing, HBB gene sequencing, and complete hemoglobinopathy workups.
• Huntsman Cancer Institute — adult bone marrow transplant program at the University of Utah, for patients pursuing curative HSCT.
• Utah Department of Health newborn screening program — for families with newly identified hemoglobinopathies in infants.

For carrier testing, family planning decisions, and prenatal diagnosis discussions, ask your hematologist for a referral to a genetic counselor. Genetic counseling for thalassemia is non-directive: the counselor provides information about risks and options without telling you what to choose. This is especially valuable for couples where both partners are carriers, and for families considering preimplantation genetic diagnosis.

• Manufacturer patient assistance programs exist for most chelators, luspatercept, mitapivat, and gene therapies. Ask your specialty pharmacy.
• HealthWell Foundation, Patient Access Network (PAN), and Patient Advocate Foundation all have programs that may help with copays for chronic therapies.
• Cooley's Anemia Foundation patient assistance can help with specific needs.
• Social workers at your hematology center are typically the most current source on what is available; ask for an introduction early.

The thalassemia field is moving quickly. To stay current, search for: beta thalassemia gene therapy outcomes, Casgevy long-term follow-up, Zynteglo real-world data, luspatercept BELIEVE BEYOND, mitapivat thalassemia, iron chelation comparison deferasirox deferiprone, cardiac T2* MRI thalassemia, haploidentical HSCT thalassemia, TIF guidelines 2025, and beta thalassemia carrier screening.

Casgevy (exagamglogene autotemcel) — global regulatory timeline. The UK Medicines and Healthcare products Regulatory Agency (MHRA) was the first regulatory authority in the world to approve Casgevy, in November 2023 — initially for sickle cell disease, making it the first approved CRISPR gene-editing therapy anywhere. The Bahrain National Health Regulatory Authority (NHRA) followed in December 2023. The US FDA approved Casgevy for sickle cell disease in December 2023 and for transfusion-dependent beta-thalassemia in January 2024. The Saudi Food and Drug Authority (SFDA) approved it in January 2024. The European Medicines Agency (EMA) granted conditional marketing authorization in February 2024.

Zynteglo (betibeglogene autotemcel). The EMA granted conditional approval for Zynteglo in 2019, but bluebird bio withdrew from the European market in 2021 over pricing and reimbursement disagreements with individual national health systems — not over safety concerns. Zynteglo remains a US-only commercial product. The FDA approved it in August 2022.

The global equity challenge. The highest burden of beta-thalassemia falls on South and Southeast Asia (India, Pakistan, Bangladesh, Thailand, Myanmar), the Middle East (Iran, Iraq, Saudi Arabia), and the Mediterranean basin. One-time gene therapies priced at $2–3 million per patient are hardest to deliver precisely where the need is greatest. Access programs, technology transfer agreements, and regional manufacturing are all being explored, but progress is slow. This gap between what is scientifically possible and what is practically available is the defining challenge for the next decade of thalassemia care.

Thalassaemia International Federation (TIF). Headquartered in Nicosia, Cyprus, TIF is the umbrella patient organization with 232 member-associations across 62 countries. TIF publishes the authoritative Guidelines for the Management of Transfusion Dependent Thalassaemia (most recent major edition 2021, published in HemaSphere 2022), which serves as the clinical reference standard worldwide. The 5th edition (2025) has updated curative therapy recommendations.

Several countries have demonstrated that organized carrier screening combined with genetic counseling can profoundly reduce the incidence of new severe thalassemia cases.

Iran introduced mandatory premarital carrier screening in 1997, making it one of the most successful national thalassemia prevention programs worldwide. Couples found to both be carriers receive genetic counseling before marriage; the program led to a dramatic reduction in new TDT births across the country.

Cyprus implemented a carrier screening program that has nearly eliminated new TDT births on the island. In a population where approximately 1 in 7 people carry a beta-thalassemia mutation, the program has been maintained for decades with strong community support.

Sardinia (Italy) achieved similar results through voluntary screening combined with genetic counseling and prenatal diagnosis, reducing the number of new TDT cases from dozens per year to near zero.

These programs demonstrate that the disease burden of beta-thalassemia is preventable at the population level when carrier identification and genetic counseling are made accessible, voluntary, and culturally appropriate. In the United States, where screening is not systematic, families with ancestry from high-prevalence regions should proactively request carrier testing, especially before pregnancy.

Beta-thalassemia care is best delivered at specialized centers with high-volume experience in transfusion management, MRI iron monitoring, chelation optimization, and curative therapy referral. The following is a representative — not exhaustive — list.

• TDT (Transfusion-Dependent Thalassemia): The severe form requiring regular red cell transfusions, typically every 3–5 weeks, to maintain adequate hemoglobin levels. Previously called thalassemia major or Cooley's anemia.
• NTDT (Non-Transfusion-Dependent Thalassemia): An intermediate form in which patients may not need regular transfusions under normal conditions, but may require them during illness, pregnancy, surgery, or growth. Previously called thalassemia intermedia.
• MCV (Mean Corpuscular Volume): A measure of the average size of red blood cells. In beta-thalassemia, MCV is characteristically low (microcytic). Also low in iron deficiency, which must be distinguished.
• MCH (Mean Corpuscular Hemoglobin): A measure of the average hemoglobin content per red blood cell. Low in beta-thalassemia (hypochromic).
• HbA2 (Hemoglobin A2): A minor hemoglobin composed of two alpha and two delta globin chains. Elevated HbA2 (typically >3.5%) is the hallmark laboratory finding of beta-thalassemia trait (carrier status).
• HbF (Fetal Hemoglobin): The form of hemoglobin normally produced during fetal development and gradually replaced by adult hemoglobin (HbA) after birth. In beta-thalassemia, HbF may remain elevated. Casgevy works by reactivating fetal hemoglobin production.
• Chelation: The use of medications (deferoxamine, deferasirox, or deferiprone) that bind excess iron in the body and allow it to be excreted in urine or stool. Essential for preventing iron-related organ damage in transfused patients.
• T2* MRI (T2-star MRI): A specialized magnetic resonance imaging technique that measures iron concentration in the heart and liver non-invasively. A cardiac T2* below 20 milliseconds indicates iron loading; below 10 milliseconds indicates high risk. This technology transformed thalassemia outcomes by enabling targeted chelation before organ damage occurred.
• HSCT (Hematopoietic Stem Cell Transplant): A procedure that replaces a patient's bone marrow with healthy donor stem cells. The oldest curative therapy for beta-thalassemia, with over 40 years of experience. Requires a compatible donor and myeloablative conditioning chemotherapy.
• REMS (Risk Evaluation and Mitigation Strategy): An FDA-mandated safety program for certain medications with serious risks. Mitapivat (Aqvesme) is dispensed under a REMS because of its risk of liver injury and the danger of sudden hemolysis if discontinued abruptly.
• Lentiviral gene therapy (Zynteglo): A gene addition approach in which a modified lentivirus delivers a functional copy of the beta-globin gene into the patient's own stem cells. The stem cells are then re-infused after myeloablative conditioning. The inserted gene produces a modified beta-globin (called beta-A-T87Q) that allows the cells to make functional hemoglobin.
• CRISPR gene therapy (Casgevy): A gene editing approach in which the CRISPR-Cas9 system is used to disable the BCL11A gene in blood-forming stem cells. With BCL11A switched off, the body resumes producing fetal hemoglobin in sufficient quantities to compensate for deficient adult hemoglobin. No new gene is added; instead, an existing silencer is removed.
• Beta-globin: One of the two protein chains (the other being alpha-globin) that pair up to form adult hemoglobin (HbA). Mutations in the beta-globin gene (HBB) cause beta-thalassemia.